Shares of Penumbra Inc. (NYSE:PEN) were down 1.4% on Tuesday . The stock traded as low as $72.24 and last traded at $72.46, with a volume of 100,990 shares changing hands. The stock had previously closed at $73.47.

Several analysts have weighed in on PEN shares. Canaccord Genuity reaffirmed a “buy” rating on shares of Penumbra in a research report on Tuesday, May 10th. Zacks Investment Research raised Penumbra from a “hold” rating to a “buy” rating and set a $68.00 price objective on the stock in a research report on Tuesday, July 12th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $56.75.

The company has a market cap of $2.26 billion and a PE ratio of 945.97. The company has a 50 day moving average price of $66.17 and a 200 day moving average price of $54.86.

Penumbra (NYSE:PEN) last announced its quarterly earnings results on Tuesday, August 9th. The company reported $0.01 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.07) by $0.08. During the same period in the previous year, the business posted ($0.11) EPS. The business earned $65.10 million during the quarter, compared to the consensus estimate of $58.18 million. The firm’s revenue was up 53.9% on a year-over-year basis. Equities analysts predict that Penumbra Inc. will post ($0.17) earnings per share for the current year.

Penumbra, Inc (Penumbra) is an interventional therapies company. The Company designs, develops, manufactures and markets medical devices. The Company has a portfolio of products that addresses medical conditions and significant clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.